Core Viewpoint - Lepu Biopharma-B (02157) has seen a significant stock increase of over 6%, currently trading at 9.66 HKD, following the announcement of its ADC drug MRG004A being included in the list of breakthrough therapies by the National Medical Products Administration [1] Company Developments - MRG004A is a novel ADC drug targeting tissue factor (TF) using innovative coupling technologies, marking a major breakthrough in ADC drug development for Lepu Biopharma [1] - The drug has received IND approval in both China and the U.S., along with orphan drug designation and fast track status from the FDA for the treatment of pancreatic cancer [1] - Lepu Biopharma has initiated a Phase III clinical trial for MRG004A in pancreatic cancer as of August 1, 2023, aiming to provide a new treatment option for patients [1] Clinical Research Insights - Previous Phase I clinical studies in the U.S. and China have shown anti-tumor activity signals in indications such as pancreatic cancer, triple-negative breast cancer, and cervical cancer [1]
港股异动 | 乐普生物-B(02157)涨超6% 自研TF ADC药物MRG004A纳入突破性治疗